Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentasa Once Daily vs Twice Daily for Maintenance of Remission in Ulcerative Colitis
NCT00209300Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- May 2005
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, single-blind trial of Salcrozine in ulcerative colitis (UC) (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Remission rate based on UC-DAI score at 12 months. Started May 2005; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00209300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209300.